Tortoise costume represents 'resilience' for fundraiser
A man will dress up as a tortoise while completing a 24 mile charity walk to reflect the resilience seen by children undergoing cancer treatment.
The inspiration for Dave Southby's outfit came from children's cancer charity CALM's logo, which is based on the story of The Hare and the Tortoise.
"Cancer treatment for children can often last for months, and in some cases years," Mr Southby said. "So it made sense for me to reflect that resilience across those 24 miles."
Mr Southby will be joined by work colleagues on the walk from Bath to Devizes on 6 September to raise money for the Swindon charity.
CALM is run by parents and supports families with children going through cancer treatment in the Swindon and Marlborough area.
Fran Robinson, who works for CALM, said that the tortoise has been part of the CALM logo since it was formed in 1984 and aims to give hope to affected families that "slow and steady will win the race".
More news stories for Wiltshire
Listen to the latest news for Wiltshire
Mr Southby, who is CEO at Swindon-based Southby & Co Financial Planning, will dress up as a tortoise for the entirety of the trek, with his team adding they will make sure he stays "safe and cool" in his costume.
Ms Robinson said: "Like many charities, CALM has been impacted by rises in the cost of living. Just to keep the same support services running, we need to raise more money every year."
The walk will journey through villages and towns, pausing in places like Bradford-upon-Avon, where the team are encouraging onlookers to come and support the charity.
"CALM was an obvious choice for me as a local charity deserving of support," Mr Southby said.
"Being a new dad myself, I've learned that it's challenging being a parent, let alone having a child with cancer and going through those unimaginable circumstances.
"If we can try and help families going through it, that's the best thing we can do."
Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Men to share stories of grief on charity walk
'Inspiring' woman, 99, to walk 200 miles for charity
Pair complete 100km walk for mental health charity
CALM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
8 hours ago
- New York Post
Grieving parents awarded $2.25M after Georgia doctor plastered videos of their decapitated baby on social media
A Georgia couple whose baby was decapacitated during childbirth was awarded a $2.25 million verdict after their pathologist posted graphic autopsy videos on social media without their consent. Dr. Jackson Gates and his Atlanta-based business will have to fork over the large sum to Jessica Ross and Traveon Taylor Sr. after a Fulton County jury found him liable of emotional distress, invasion of privacy, and fraud on Wednesday. 'This young couple trusted him with the remains of their precious baby,' attorney's for the grieving parents said, noting that the doctor 'poured salt into the couple's already deep wounds.' 3 Jessica Ross and Treveon Taylor Sr., parents of a baby who was decapitated during childbirth. AP 'Gates, in turn, repaid this trust by posting horrific images of their child for the world to see.' The heartbroken couple hired the twisted doctor to perform an autopsy on their deceased newborn two days after their obstetrician allegedly applied excessive force to the baby's neck when its shoulders became stuck in Ross's pelvic area, causing it to detach during the traumatic July 2023 delivery. 3 The traumatic delivery occurred at Southern Regional Medical Center in July 2023. ERIK S LESSER/EPA-EFE/Shutterstock The baby's head was delivered vaginally, but the rest of the body was removed via C-section. The death was later ruled a homicide. Gates posted numerous videos and photos to his Instagram later that month, showing the grisly postmortem examination of their infants 'decapitated, severed head,' the couple said in their lawsuit. The deranged pathologist initially removed the footage after receiving a letter from the couple's attorney — but later reposted them, according to the lawsuit. 3 The couple was awarded $2.25 million in a lawsuit against their pathologist. AP Gates' attorney, Ira Livant, said his client typically documents his autopsy's on social media to educate fellow pathologists and highlight the importance of independent examinations in cases where families suspect medical misconduct. 'Dr. Gates testified that he is deeply sorry for any harm that he unintentionally caused the plaintiffs,' Livant said Saturday. 'Had he known for one second that they would see that and that they would know it was their child, he would never have done it.' The couple will receive $2 million in compensatory damages and an additional $250,000 in punitive damages from Gates and his company, Medical Diagnostics Choices, per the judgement. The bereaved parents have separate lawsuits pending against the delivering doctor and the Riverdale hospital where the horrific incident took place. With Post wires.
UPI
11 hours ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
Yahoo
18 hours ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
